Contents

PREMED II: prevention of cystoid macular edema after cataract surgery in diabetics

July, 2018

Clinical trial

Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2.

Wielders LHP, Schouten JSAG, Winkens B, van den Biggelaar FJHM, Veldhuizen CA, Murta JCN, Goslings WRO, Kohnen T, Tassignon MJ, Joosse MV, Henry YP, Nagy ZZ, Rulo AHF, Findl O, Amon M, Nuijts RMMA.

J Cataract Refract Surg. 2018 Jul;44(7):836-847.
Full text | Metrics.

Main finding: Diabetic patients who received subconjunctival triamcinolone at the end of cataract surgery had a lower macular thickness and volume at six and 12 weeks postoperatively than patients who did not. Intravitreal bevacizumab had no significant effect.

 

  • Purpose: To compare the efficacy of subconjunctival triamcinolone or intravitreal bevacizumab to reduce the risk of developing cystoid macular edema after uneventful cataract surgery in diabetic patients.
  • Study type: Randomized controlled trial
  • Condition: Cataract surgery in diabetics

Participants: ≥21 years requiring phacoemulsification cataract surgery, diabetics

 

  • n=213

 

Intervention:

 

Group 1: No additional treatment
Group 2: Subconjunctival triamcinolone acetonide 40mg
Group 3: Intravitreal bevacizumab 1.25mg
Group 4: Combination of subconjunctival triamcinolone and intravitreal bevacizumab

Patients who received subconjunctival triamcinolone had signficantly decreased macular thickness than those who did not.

 

No patient who received subconjunctival triamcinolone acetonide developed cystoid macular oedema.

 

Intravitreal bevacizumab had no significant effect on macular thickness.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed